Product
ARQ197
1 clinical trial
2 indications
Indication
cancerIndication
Small CellClinical trial
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two StageStatus: Terminated, Estimated PCD: 2017-02-21